Want to see JP:4527 full AI Analyst Report?
Total Valuation
Rohto Pharmaceutical Co has a market cap or net worth of ¥578.42B. The enterprise value is ¥539.70K.
Market Cap¥578.42B
Enterprise Value¥539.70K
Share Statistics
Rohto Pharmaceutical Co has 236,178,310 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding236,178,310
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Rohto Pharmaceutical Co’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 8.32%.
Return on Equity (ROE)0.12
Return on Assets (ROA)0.07
Return on Invested Capital (ROIC)8.32%
Return on Capital Employed (ROCE)0.12
Revenue Per Employee33.21M
Profits Per Employee3.34M
Employee Count9,292
Asset Turnover0.73
Inventory Turnover2.26
Valuation Ratios
The current PE Ratio of Rohto Pharmaceutical Co is 16.1. Rohto Pharmaceutical Co’s PEG ratio is 1.40.
PE Ratio16.1
PS Ratio1.58
PB Ratio1.80
Price to Fair Value1.96
Price to FCF14.99
Price to Operating Cash Flow―
PEG Ratio1.40
Income Statement
In the last 12 months, Rohto Pharmaceutical Co had revenue of 308.63B and earned 31.00B in profits. Earnings per share was 136.11.
Revenue308.63B
Gross Profit169.46B
Operating Income38.47B
Pretax Income42.33B
Net Income31.00B
EBITDA56.42B
Earnings Per Share (EPS)136.11
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Rohto Pharmaceutical Co pays an annual dividend of ¥25, resulting in a dividend yield of 1.53%
Dividend Per Share¥25
Dividend Yield1.53%
Payout Ratio26.02%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.46
52-Week Price Change21.17%
50-Day Moving Average2.41K
200-Day Moving Average2.44K
Relative Strength Index (RSI)57.23
Average Volume (3m)643.03K
Important Dates
Rohto Pharmaceutical Co upcoming earnings date is Aug 6, 2026, TBA (Confirmed).
Last Earnings DateMay 13, 2026
Next Earnings DateAug 6, 2026
Ex-Dividend Date―
Financial Position
Rohto Pharmaceutical Co as a current ratio of 2.30, with Debt / Equity ratio of ―
Current Ratio2.30
Quick Ratio1.65
Debt to Market Cap0.11
Net Debt to EBITDA-0.28
Interest Coverage Ratio40.53
Taxes
In the past 12 months, Rohto Pharmaceutical Co has paid 11.38B in taxes.
Income Tax11.38B
Effective Tax Rate0.27
Enterprise Valuation
Rohto Pharmaceutical Co EV to EBITDA ratio is 8.75, with an EV/FCF ratio of 17.73.
EV to Sales1.60
EV to EBITDA8.75
EV to Free Cash Flow17.73
EV to Operating Cash Flow13.37
Balance Sheet
Rohto Pharmaceutical Co has ¥75.84B in cash and marketable securities with ¥60.24B in debt, giving a net cash position of ¥26.96B billion.
Cash & Marketable Securities¥75.84B
Total Debt¥60.24B
Net Cash¥26.96B
Net Cash Per Share¥114.14
Tangible Book Value Per Share¥945.43
Margins
Gross margin is ―, with operating margin of 12.46%, and net profit margin of 10.05%.
Gross Margin―
Operating Margin12.46%
Pretax Margin13.72%
Net Profit Margin10.05%
EBITDA Margin18.28%
EBIT Margin14.02%
Analyst Forecast
The average price target for Rohto Pharmaceutical Co is ¥2,950.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target¥2,950.00
Price Target Upside15.23% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast11.37%
EPS Growth Forecast11.35%